Regulatory update log
A chronological log of UK regulatory actions (MHRA, NICE, EMA, WADA) affecting peptide and GLP-1 medicines that have prompted updates to Peptide Authority content.
Last reviewed:
This is the running log of UK regulatory actions affecting peptide and GLP-1 medicines that have prompted updates to Peptide Authority content. Most-recent first. The full narrative version (with context) is at counterfeit medicine timeline; this page is the structured changelog.
- MHRAFebruary 2026Read the relevant page →
Falsified Mounjaro 15 mg KwikPens reach UK patients
MHRA alert: counterfeit Mounjaro 15 mg pens via unlicensed online supply. Unexpected adverse reactions and inconsistent effects suggest contents are not genuine tirzepatide at the stated concentration.
- MHRA2026 (ongoing)Read the relevant page →
Disruption of illegal weight-loss medicine manufacturing
MHRA and partners report disruption of illegal manufacturing networks producing unlicensed compounded GLP-1 supply marketed to UK consumers via online clinics that bypass real clinical assessment.
- MHRA2025Read the relevant page →
‘Compounded semaglutide’ enforcement begins
MHRA began acting against UK online clinics marketing ‘compounded semaglutide’ as a cheap Wegovy alternative. Enforcement basis: unlicensed-medicine supply outside the ‘specials’ framework.
- MHRA2025Read the relevant page →
Counterfeit Ozempic — sustained UK border seizures
Sustained pressure on Ozempic supply kept the counterfeit market active through 2025. Some seized pens contained insulin rather than semaglutide — a direct hypoglycaemia risk for non-diabetic users.
What counts as a regulatory update
We treat the following as triggers for adding an entry to this log:
- An MHRA Drug Safety Update or recall notice affecting any compound covered here.
- A new NICE Technology Appraisal or Guideline that affects access to a medicine we cover (e.g. TA875 Wegovy, TA1026 Mounjaro).
- An EMA marketing-authorisation change, withdrawal, or referral.
- A WADA Prohibited List change adding or removing a peptide we cover.
- Significant MHRA enforcement action — convictions, large seizures, falsified-product alerts.
Updates to NHS access pathways, NICE recommissioning decisions, and regional commissioning changes are also logged when they materially affect what we publish about a UK access route.
What this log is not
This is not a comprehensive index of every MHRA announcement or NICE document published in the UK. It is the log of regulatory events that prompted Peptide Authority to update or add content. Readers seeking a comprehensive UK regulatory feed should consult MHRA Drug Safety Update, NICE guidance, and the WADA Prohibited List directly.